Category Archives: Mesenchymal Stem Cells

Children's Healthcare of Atlanta and Winship Cancer Institute target graft-versus-host-disease through immune cell therapy An innovative clinical trial using the science of "personalized" cellular therapy has begun enrolling children and adults suffering from graft-versus-host-disease (GVHD), a life-threatening complication of bone marrow transplantation in which donor immune lymphocytes attack the organs of the bone marrow transplant recipient. Bone marrow transplantation is performed in some patients with cancers of the blood or bone marrow, including multiple myeloma and leukemia, as well as in some patients with sickle cell disease, thallesemia, aplastic anemia and inherited immune deficiency. Physician-researchers at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University will harvest bone marrow cells from children and adults (12 to 65 years) with GVHD. Those cells will be used to manufacture large numbers of personalized autologous marrow mesenchymal stromal cells in the Emory Personalized Immunotherapy Center (EPIC), a dedicated pharmaceutical grade facility located within Emory University Hospital. By infusing large doses of these personalized bone marrow cells into bone marrow transplant recipients, the physician-researchers aim to target sites of inflammation, potentially reducing GVHD in the intestine, liver and skin and limiting long-term organ damage. … Continue reading →

Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center How can PRP and stem cell therapy help you heal? Orlando Orthopaedic Center's Dr. Matthew R. Willey explains. For more visit http://www.OrlandoOrtho.com. By: OrlandoOrtho … Continue reading →

A new study has identified an enzyme in mesenchymal stem cells (MSCs) that is responsible for creating either bone or fat a finding that scientists argue may lay the groundwork for new osteoporosis and obesity treatments. Researchers at the Interdisciplinary Stem Cell Institute (ISCI), at the University of Miami Miller School of Medicine, say their findings are preliminary but promising. We got very interested in the idea of there are all of these diseases of the bone that plague human beings, so we wondered if we understood the cells better, would we able to understand their role in diseases, lead study author Dr. Joshua Hare, founding director of ISCI, told FoxNews.com. The study was conducted using mice that lacked an enzyme that regulates the level of nitric oxide signaling, a key in determining whether MSCs become fat or bone cells. MSCs from the mice that genetically lacked the enzyme made more bone cells and fewer fat cells. The researchers identified the switch, called a GSNOR, which they believe will translate clinically to help better understand how drugs may be able to manipulate the GSNOR, possibly offering future treatment for obesity and bone-disease related illnesses. Drugs do exist to block the … Continue reading →

First Canadian clinical trial studying ability of mesenchymal cells to treat multiple sclerosis The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEsenchymal Stem cell therapy for CAnadian. By: HSC Winnipeg … Continue reading →

Costa Mesa and Sherman Oaks, California (PRWEB) March 31, 2015 The Irvine Stem Cell Treatment Center announces a series of free public seminars on the use of adult stem cells for various degenerative and inflammatory conditions. They will be provided by Dr. Thomas A. Gionis, Surgeon-in-Chief. The seminars will be held on Wednesday, April 8, 2015, at 11:00 am, 1:00 pm and 3:00 pm at Ayres Hotel & Suites Costa Mesa/Newport Beach, 325 Bristol Street, Costa Mesa, CA 92626; and Wednesday, April 22, 2015, at 11:00 am, 1:00 pm and 3:00 pm at Hampton Inn, 5638 Sepulveda Blvd., Sherman Oaks, CA 91411. Please RSVP at (949) 679-3889. The Irvine Stem Cell Treatment Center (Irvine and Westlake), along with sister affiliates, the Miami Stem Cell Treatment Center (Miami; Boca Raton; Orlando; The Villages; Sarasota, Florida) and the Manhattan Regenerative Medicine Medical Group (Manhattan, New York), abide by approved investigational protocols using adult adipose derived stem cells (ADSCs) which can be deployed to improve patients quality of life for a number of chronic, degenerative and inflammatory conditions and diseases. ADSCs are taken from the patients own adipose (fat) tissue (found within a cellular mixture called stromal vascular fraction (SVF)). ADSCs are exceptionally … Continue reading →

Durham, NC (PRWEB) March 31, 2015 Stem cells may provide Crohns disease sufferers relief from a common, potentially dangerous side effect fistulas according to the results of a phase 2 clinical trial published in the latest issue of STEM CELLS Translational Medicine (SCTM). After receiving an injection of their own adipose-derived stem cells (ASC), which are collected from fat tissue, the fistulas in 75 percent of the trial participants were completely healed within eight weeks of their last treatment and remained so two years later. Crohn's disease is a painful, chronic autoimmune disorder in which the body's immune system attacks the gastrointestinal tract. Inflammation in Crohns patients can sometimes extend completely through the intestinal wall and create a fistula an abnormal connection between the intestine and another organ or skin. Left untreated, a fistula might become infected and form an abscess, which in some cases can be life threatening. Chang Sik Yu, M.D., Ph.D., of Asan Medical Center in Seoul, Korea, a senior author of the SCTM paper, describes the results of a clinical trial conducted in collaboration with four other hospitals in South Korea, stated, Crohns fistula is one of the most distressing diseases as it decreases patients quality … Continue reading →

Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model... Intrapericardial Administration of Mesenchymal Stem Cells in a Large Animal Model: A Bio-Distribution Analysis. Rebeca Blzquez et al (2015), PLoS ONE http://journals.plos.org/plosone/article?id=1... By: KeSimpulan … Continue reading →

Cynata V04 Explainer video, developed by Planet Innovation, on Cynata's Cymerus technology which produces mesenchymal stem cells for therapeutic application, consistent... By: Roger Langsdon … Continue reading →

EVEN without surgery, one can now experience a dramatic improvement and even cure on health concerns such as diabetes, cancer, HIV, and cardiovascular diseases. This is through the stem cell technology and telomere science. Dr. Marc Lavaro Jr., an expert on general & ocular oncology, general & ocular pharmacology, pediatric ophthalmic medicine, and Science of Epigenetics said these new technology are considered as breakthrough which repairs and rejuvenates the cells. Lavaro, head of a molecular biology research in Gifu Prefecture, Japan and Osato Research Institute, Tokyo Japan stressed that stem cell is a kind of cell that can duplicate all kinds of cell which is why it can repair a damaged heart for instance. In his book entitled 278+ Growth Factors which he is set to publish, he also mentioned that there are also certain organs which do not regenerate like the heart and brain but through stem cells it can revitalize. Growth factors are stem cell stimulators that address medical conditions including diseases. Each growth factor is equivalent to 1 disease. For example, in a tumor kidney problem, stem cells produce growth factors to combat it. Another technology is the telomere science under science of Epigenetics. Telomere is part … Continue reading →

Biotech company AmnioChor is bringing new life to perinatal stem cell technology and an alternative to the cord blood banking industry. Currently, parents have an option to allow cord blood to be stored in a public bank, which could be used for research or unrelated transplants. Alternatively, they can pay to have cells stored in a family bank, which will allow them personal access. What makes AmnioChors technology different is the process of freezing a whole piece of the amnion placental tissue, which contains the Mesenchymal and Epithelial stem cells. This approach would provide many more opportunities to use the cells, and these cells have unique qualities that differentiate them from cord blood. Cord blood technology separates and processes the cells, so the use is more limited. AmnioChor will store samples as if they were in a blood bank essentially (theirs is called Omnibank). Parents can choose to store placental tissue there for future personal use, and samples that come from donations will be stored as well. The company hopes to close a $300,000 seed round in the next six months to develop the concept, CEO Russ Schweizer said. AmnioChor is part of Chicagos MATTER healthcare incubator. Its product is … Continue reading →